620
Participants
Start Date
December 31, 2013
Primary Completion Date
March 31, 2016
Study Completion Date
September 30, 2016
TRV027 Dose #1
TRV027 continuous intravenous infusion Dose #1
TRV027 Dose #2
TRV027 continuous intravenous infusion Dose #2
TRV027 Dose #3
TRV027 continuous intravenous infusion Dose #3
Placebo
Placebo continuous intravenous infusion
Tennessee Center for Clinical Trials, Tullahoma
University of Cincinnati, Cincinnati
Wayne State University, Detroit
Michael E Debakey VA Medical Center, Houston
Research Site, Buenos Aires
Research Site, Coronel Suárez
Research Site, Corrientes
Research Site, Córdoba
Research Site, La Plata
Research Site, Morón
Research Site, Quilmes
Research Site, Rosario
Research Site, San Martín
Research Site, San Miguel de Tucumán
Research Site, Santa Fe
Research Site, Dimitrovgrad
Research Site, Kazanlak
Research Site, Pazardzhik
Research Site, Pleven
Research Site, Smolyan
Research Sites, Sofia
Research Site, Sofia
Research Site, Edmonton
Research Site, Ottawa
Research Site, Brno
Research Site, Hradec Králové
Research Site, Olomouc
Research Site, Prague
Research Site, Berlin
Research Site, Dortmund
Research Site, Greifswald
Research Site, Budapest
Research Site, Kaposvár
Research Site, Pécs
Research Site, Afula
Research Site, Ashkelon
Research Site, Hadera
Research Site, Haifa
Research Site, Jerusalem
Research Site, Nahariya
Research Site, Nazareth
Research Site, Safed
Research Site, Bad Nauheim
Research Site, Bialystok
Research Site, Grodzisk Mazowiecki
Research Site, Krakow
Research Site, Kłodzko
Research Site, Lublin
Research Site, Ruda Śląska
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Baia Mare
Research Site, Bucharest
Research Site, Cluj-Napoca
Research Site, Craiova
Research Site, Târgu Mureş
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Saratov
Research Site, Bratislava
Research Site, Kocise
Research Site, Martin
Trevena Inc.
INDUSTRY